Nyxoah SA NYXH 深 滬
等待開盤 08-21 09:30:00 美东时间
1.64
-0.010
-0.61%
華盛通- 最 高1.695
- 今 開1.64
- 成交量 3.92万股
- 最 低 1.64
- 昨 收 1.65
- 總市值 1.64亿
- 52周最高 6.8745
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 1.26
- 委 比 88.25%
- 總股本 1.00亿
- 歷史最高 37.00
- 量 比 0.35
- 振 幅 3.33%
- 歷史最低 1.26
- 每 手 1
- 風險率 1.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $6
Cantor Fitzgerald analyst Sarah James maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $11 to $6.
08-17 19:15
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $6
Piper Sandler analyst Adam Maeder reiterates Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $7 to $6.
08-07 00:43
Nyxoah Reports Preliminary Q2 Global Net Revenue Of ~€7.7M, Reiterates FY26 Global Net Revenue Range €36M - €40M
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating r...
07-08 04:08
Nyxoah Announces Preliminary Results for the Second Quarter of 2026
Nyxoah reported second quarter 2026 preliminary results with global net revenue of €7.7 million, up 21% sequentially, driven by U.S. growth of 22% to €5.2 million. Key U.S. metrics include 55 new surgeons trained, 89 new accounts activated, and 427 patients submitted under prior authorization. CMS proposed a 12% increase in hospital reimbursement and 15% in ASC reimbursement for the Genio procedure. Nyxoah secured $110 million in financing, with ...
07-07 20:05
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
Nyxoah Receives $15M Second Tranche Proceeds From Its Loan Facility With European Investment Bank
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it has received $15 million (€13.8 million) in proceeds from the second tranche of its loan facility...
06-18 04:06
Stifel Maintains Hold on Nyxoah, Lowers Price Target to $3
Stifel analyst Jonathan Block maintains Nyxoah (NASDAQ:NYXH) with a Hold and lowers the price target from $5 to $3.
06-18 01:14
Nyxoah Receives $15 Million from the European Investment Bank
Nyxoah has received $15 million from the European Investment Bank, bringing its total capital raised in June 2026 to $110 million. The funds will accelerate the commercial launch of its Genio system in the U.S., support R&D, and expand manufacturing. Genio, a hypoglossal neurostimulation therapy for Obstructive Sleep Apnea, has received CE and FDA approvals. This non-dilutive financing strengthens Nyxoah's balance sheet, enabling growth and innov...
06-17 20:05
